Clinical trial
A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00655837 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2008
- Completion date
- February 28, 2010
- Enrollment
- 33 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.